ArticleBMC cancer2026
PLIN1 restoration modulates lipid reprogramming and impedes tumor growth in ovarian cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundOvarian cancer (OC) is an aggressive gynecologic malignancy characterized by remarkable metabolic reprogramming. Lipid metabolic remodeling is closely associated with malignant proliferation, metastasis, and therapeutic resistance, but key regulators remain incompletely understood.
methodsIntegrated lipid metabolomics and transcriptome sequencing analyses were performed using paired OC and adjacent non-tumor tissues. Differential lipids (VIP > 1.5 and false discovery rate [FDR]-adjusted P < 0.05) and differentially expressed genes (|log2FC| > 1 and FDR-adjusted P < 0.05) were screened and integrated with lipid metabolism-related gene sets. PLIN1 expression and function were further evaluated in clinical samples, OC cell lines, and xenograft models.
resultsPerilipin 1 (PLIN1) was identified as a candidate lipid metabolism-related hub gene with previously underexplored roles in OC. PLIN1 was downregulated in clinical OC specimens and OC cell lines. PLIN1 expression was negatively associated with carnitine palmitoyltransferase 1 A (CPT1A), and positively associated with acyl-CoA synthetase long-chain family member 3 (ACSL3), acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FASN), and stearoyl-CoA desaturase 1 (SCD1). Functionally, PLIN1 overexpression suppressed cell viability, migration, and invasion; promoted intracellular lipid accumulation and lipid droplet formation; increased several lipid storage/lipogenesis-associated enzymes; and decreased CPT1A expression. In vivo, PLIN1 overexpression inhibited xenograft tumor growth, enhanced lipid deposition, reduced Ki67 expression, and was accompanied by decreased HSL, ATGL, and p-CREB expression.
conclusionsThese findings suggest that PLIN1 may suppress OC progression, at least in part, by reshaping lipid storage and lipolysis-related metabolic signaling. Further studies are required to define the direct regulatory mechanisms and validate its clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.